Optimize MSI testing to facilitate better access to immunotherapy for all patients.
Colorectal cancer (CRC) is the second most common cause of death by cancer worldwide and Microsatellite Instability (MSI), a genomic biomarker, plays an important role in determining treatment.
MSI status represents 15% of the CRC population and immunotherapy has been approved for this subset of patients—prompting guidelines for universal screening. Furthermore, MSI status is reported to be predictive of response to immunotherapy across all solid tumors.
MSI tumors can also arise from a hereditary condition which increases the risk of developing cancers in multiple organs (Lynch syndrome). It is key to identify these patients and provide them with closer follow-up.
As demand for MSI screening for CRC patients (and beyond) increases, so too does the testing burden for pathologists and labs— creating bottlenecks and resource pressures.
Scientific development milestones
Peer reviewed research in Nature Communications 2020
Science presented at COMPAY workshop
MSIntuit CRC uses H&E slides to rule out MSS phenotypes due to equivalent sensitivity when compared to standard testing techniques — saving pathologists and oncologists time and resources.
Suitable for adults with primary colorectal cancer
Sensitivity is on par with the highest current standards of MSI screening
MSIntuit CRC is 95% sensitive and 46% specific, enabling an early rule-out of 40% of cases¹
A step towards increased lab capacity
Training the AI algorythm
*MsIntuit CRC was trained on hundreds of histology slides for which the MSI status was known , enabling the diagnostic to indetify MSI/MSS phenotypes directly on H&E Slides
Much of a histopathologist’s day is absorbed by tedious and repetitive tasks supplemented by the increased number of cases to run. Considering the global shortage of pathologists, an obvious step is to use AI to automate such tasks— a move that could also mitigate problems of intra- and inter-observer variability in histopathology. Owkin’s automated dMMR/MSI screening tool could improve the management of colorectal cancers for which the screening is very important. This diagnostic solution could make dMMR/MSI screening faster and more efficient.
Professor of Clinical Artificial Intelligence Else Kröner Fresenius Center for Digital Health, Technical University Dresden
MSIntuit CRC is CE-IVD marked for diagnostic use in the EU. In all other countries including the United States, the use of MSIntuit CRC is limited to Research Use Only, not for use in diagnostic procedures. For detailed information on regulatory or safety information, system configuration and indications for use, contact Owkin.
Images shown may represent the range of product, or be for illustration purposes only, and may not be an exact representation of the product.
(1) Svrcek M, Saillard C, Dubois R, et al. Blind validation of MSIntuit, an AI-based pre-screening tool for MSI detection from colorectal cancer H&E slides. Poster presented at: European Society for Medical Oncology (ESMO); May 9th - 13th 2022; Paris France.
Take a closer look